These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1178 related articles for article (PubMed ID: 23830843)
1. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations. Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843 [TBL] [Abstract][Full Text] [Related]
2. Small-dense LDL/large-buoyant LDL ratio associates with the metabolic syndrome. Srisawasdi P; Vanavanan S; Rochanawutanon M; Kruthkul K; Kotani K; Kroll MH Clin Biochem; 2015 May; 48(7-8):495-502. PubMed ID: 25645359 [TBL] [Abstract][Full Text] [Related]
3. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Milosavljevic D; Griglio S; Le Naour G; Chapman MJ Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449 [TBL] [Abstract][Full Text] [Related]
4. Lipoprotein profile in patients who survive a stroke. Oravec S; Krivosikova Z; Krivosik M; Gruber K; Gruber M; Dukát A; Gavorník P Neuro Endocrinol Lett; 2011; 32(4):496-501. PubMed ID: 21876499 [TBL] [Abstract][Full Text] [Related]
5. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863 [TBL] [Abstract][Full Text] [Related]
6. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size. Tani S; Matsumoto M; Nagao K; Hirayama A J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623 [TBL] [Abstract][Full Text] [Related]
7. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Jenkins AJ; Lyons TJ; Zheng D; Otvos JD; Lackland DT; McGee D; Garvey WT; Klein RL; Kidney Int; 2003 Sep; 64(3):817-28. PubMed ID: 12911531 [TBL] [Abstract][Full Text] [Related]
8. Relationship between unconjugated hyperbilirubinemia and lipoprotein spectrum. Očadlík I; Hlinštáková S; Oravec S Neuro Endocrinol Lett; 2011; 32(3):360-4. PubMed ID: 21712778 [TBL] [Abstract][Full Text] [Related]
9. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082 [TBL] [Abstract][Full Text] [Related]
10. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status. Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247 [TBL] [Abstract][Full Text] [Related]
11. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523 [TBL] [Abstract][Full Text] [Related]
12. NMR identifies atherogenic lipoprotein abnormalities in early diabetic nephropathy that are unrecognized by conventional analysis. Al-Shahrouri HZ; Ramirez P; Fanti P; Abboud H; Lorenzo C; Haffner S Clin Nephrol; 2010 Mar; 73(3):180-9. PubMed ID: 20178716 [TBL] [Abstract][Full Text] [Related]
13. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506 [TBL] [Abstract][Full Text] [Related]
14. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694 [TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262 [TBL] [Abstract][Full Text] [Related]
16. Increased large VLDL and small LDL particles are related to lower bilirubin in Type 2 diabetes mellitus. Dullaart RP; de Vries R; Lefrandt JD Clin Biochem; 2014 Nov; 47(16-17):170-5. PubMed ID: 25149194 [TBL] [Abstract][Full Text] [Related]
17. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension. Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744 [TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive assessment of lipoprotein subfraction profiles according to glucose metabolism status, and association with insulin resistance in subjects with early-stage impaired glucose metabolism. Lee JE; Min SH; Lee DH; Oh TJ; Kim KM; Moon JH; Choi SH; Park KS; Jang HC; Lim S Int J Cardiol; 2016 Dec; 225():327-331. PubMed ID: 27756036 [TBL] [Abstract][Full Text] [Related]
20. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Olson EJ; Pearce GL; Jones NP; Sprecher DL Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]